Table 3. IC50 values for doxorubicin treatment in the presence or absence of salinomycins.
| Cell Line | NC-Vectors | FOXO3a-TM Plasmid | ||||
|---|---|---|---|---|---|---|
| IC50 of Doxa (μg/ml) | Combination Index | IC50 of Doxb (μg/ml) | Combination Index | |||
| Dox | Dox+Sal | Dox | Dox+Sal | |||
| HuH-7 | 0.7769 | 0.5072*** | 0.7476 | 0.6381 | 0.5065** | 0.9372 |
| HepG2 | 0.1772 | 0.1283** | 0.7243 | 0.1250 | 0.1180* | 0.9458 |
| SNU-449 | 2.273 | 0.5713*** | 0.4173 | 0.4825 | 0.4117** | 0.9962 |
| SNU-387 | 1.459 | 0.5063*** | 0.5743 | 0.5811 | 0.4973*** | 1.087 |
IC50 of doxorubicin concentration in two treatments for 48 h for HCC cells with normal expression of FOXO3a
IC50 of doxorubicin concentration in two treatments for 48 h for HCC cells with high expression of FOXO3a.
p < 0.05
p < 0.01
p < 0.001.